Meta-analysis of 17 trials (16,162 patients with prostate cancer): adding any androgen receptor pathway inhibitor to ADT raised fracture risk vs ADT alone (pooled OR 1.5 to 2.4), with no difference between ARPIs; only 7 studies reported bone-protecting agent use.
Meta-analysisn = 16,162
Saporita et al. Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis